Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR.

J Clin Oncol. 2008 Sep 1;26(25):4189-99. doi: 10.1200/JCO.2007.11.5964. Review.

2.

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.

Perry JR, Rizek P, Cashman R, Morrison M, Morrison T.

Cancer. 2008 Oct 15;113(8):2152-7. doi: 10.1002/cncr.23813.

3.

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.

Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M.

J Clin Oncol. 2008 May 1;26(13):2192-7. doi: 10.1200/JCO.2007.14.8163.

PMID:
18445844
4.

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.

Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, Meyermann R, Reifenberger G, Weller M, Wick W.

J Clin Oncol. 2007 Aug 1;25(22):3357-61.

PMID:
17664483
5.

A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma.

Kong DS, Lee JI, Kim WS, Son MJ, Lim DH, Kim ST, Park K, Kim JH, Eoh W, Nam DH.

Oncol Rep. 2006 Nov;16(5):1117-21.

PMID:
17016602
6.

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.

Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE.

J Neurooncol. 2007 Mar;82(1):81-3. Epub 2006 Aug 31.

PMID:
16944309
7.

The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens.

Simon R, Norton L.

Nat Clin Pract Oncol. 2006 Aug;3(8):406-7. Review. No abstract available.

PMID:
16894366
8.

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R.

N Engl J Med. 2005 Mar 10;352(10):997-1003.

9.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group.

N Engl J Med. 2005 Mar 10;352(10):987-96.

10.

Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme.

Tuettenberg J, Grobholz R, Korn T, Wenz F, Erber R, Vajkoczy P.

J Cancer Res Clin Oncol. 2005 Jan;131(1):31-40. Epub 2004 Sep 28.

PMID:
15565458
11.

Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.

de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ.

Neurology. 2004 Aug 10;63(3):535-7. Review.

PMID:
15304589
12.

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma.

Wick W, Steinbach JP, Küker WM, Dichgans J, Bamberg M, Weller M.

Neurology. 2004 Jun 8;62(11):2113-5.

PMID:
15184628
13.

Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy--a phase-II study.

Wismeth C, Hau P, Fabel K, Baumgart U, Hirschmann B, Koch H, Jauch T, Grauer O, Drechsel L, Brawanski A, Bogdahn U, Steinbrecher A.

J Neurooncol. 2004 May;68(1):79-86.

PMID:
15174524
14.

The anti-angiogenic basis of metronomic chemotherapy.

Kerbel RS, Kamen BA.

Nat Rev Cancer. 2004 Jun;4(6):423-36. Review. No abstract available.

PMID:
15170445
15.

Inhibition of angiogenesis by non-toxic doses of temozolomide.

Kurzen H, Schmitt S, Näher H, Möhler T.

Anticancer Drugs. 2003 Aug;14(7):515-22. Review.

PMID:
12960735
16.

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.

Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman L, Statkevich P, Cutler DL, Rowinsky EK.

Br J Cancer. 2003 Apr 7;88(7):1004-11.

17.

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.

Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE.

Neuro Oncol. 2002 Jan;4(1):39-43. doi: 10.1093/neuonc/4.1.39.

18.

Retinoids inhibit human glioma cell proliferation and migration in primary cell cultures but not in established cell lines.

Bouterfa H, Picht T, Kess D, Herbold C, Noll E, Black PM, Roosen K, Tonn JC.

Neurosurgery. 2000 Feb;46(2):419-30.

PMID:
10690732
19.

Phase I trial of temozolomide using an extended continuous oral schedule.

Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ.

Cancer Res. 1998 Oct 1;58(19):4363-7.

Supplemental Content

Support Center